Skandinaviska Enskilda Banken AB publ grew its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 10.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,347 shares of the biopharmaceutical company’s stock after buying an additional 12,004 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.06% of Alexion Pharmaceuticals worth $18,259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. First Hawaiian Bank bought a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $102,000. Advisory Services Network LLC raised its position in shares of Alexion Pharmaceuticals by 145.3% during the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 523 shares during the last quarter. Checchi Capital Advisers LLC bought a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $204,000. K.J. Harrison & Partners Inc bought a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $209,000. Finally, Bbva Compass Bancshares Inc. bought a new stake in shares of Alexion Pharmaceuticals during the third quarter valued at approximately $218,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Shares of ALXN opened at $123.44 on Friday. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $140.77. The firm has a market capitalization of $28.37 billion, a P/E ratio of 23.92, a price-to-earnings-growth ratio of 1.10 and a beta of 0.99. The company has a current ratio of 3.16, a quick ratio of 2.74 and a debt-to-equity ratio of 0.32.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the previous year, the business posted $1.44 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 19.5% on a year-over-year basis. As a group, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current year.
Several research firms have recently issued reports on ALXN. BidaskClub cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Evercore ISI reiterated an “outperform” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a research report on Thursday, July 26th. ValuEngine cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 8th. Stifel Nicolaus cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $154.00 to $130.00 in a research report on Tuesday, August 7th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $123.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, July 27th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $161.29.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Recommended Story: Day Trading
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.